Drug Trial Radar · NCT07930507
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
204
Planned (sponsor's estimate)
Start
Dec 21, 2026
Primary completion
Oct 11, 2027
Study completion Oct 11, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effect on LDL-C and the safety and tolerability of FDC laroprovstat/rosuvastatin in LLT-naïve patients with hypercholesterolaemia. Laroprovstat and FDC laroprovstat/rosuvastatin are being developed for the treatment of hypercholesterolaemia.
Conditions
- Hypercholesterolemia
Interventions
LaroprovstatDrug
daily oral dose of the Laroprovstat
Rosuvastatin 1Drug
daily oral dose of the Rosuvastatin 1
Rosuvastatin 2Drug
daily oral dose of the Rosuvastatin 2
FDC laroprovstat/Rosuvastatin 1Drug
daily oral dose of the FDC Laroprovstat/Rosuvastatin 1
FDC laroprovstat/Rosuvastatin 2Drug
daily oral dose of the FDC Laroprovstat/Rosuvastatin 2
Placebo to match rosuvastatinDrug
daily oral dose of the Placebo to match Rosuvastatin
Placebo to match laroprovstat or FDC laroprovstat/rosuvastatinDrug
daily oral dose of the Placebo to match laroprovstat or FDC laroprovstat/rosuvastatin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relative change in LDL-CTime frame: Week 8
- Relative change in LDL-CTime frame: Week 8
Locations
42 sites in 6 countries. Site status is shown where the registry gives one.
Research Site
Beijing, China
Research Site
Chifeng, China
Research Site
Guangzhou, China
Research Site
Ha’erbin, China
Research Site
Hangzhou, China
Research Site
Hefei, China
Research Site
Liuzhou, China
Research Site
Luoyang, China
Research Site
Nanchang, China
Research Site
Nanjing, China
Research Site
Sanya, China
Research Site
Shanghai, China
Research Site
Shantou, China
Research Site
Shiyan, China
Research Site
Suining, China
Research Site
Tangshan, China
Research Site
Tianjin, China
Research Site
Yueyang, China
Research Site
Zhengzhou, China
Research Site
Zigong, China
Research Site
Hong Kong, Hong Kong
Research Site
Hong Kong, Hong Kong
Research Site
Hong Kong, Hong Kong
Research Site
Ampang, Malaysia
Research Site
Beseri, Malaysia
Research Site
Kuala Kedah, Malaysia
Research Site
Puchong, Malaysia
Research Site
Sarawak Miri, Malaysia
Research Site
Daegu, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Wŏnju, South Korea
Research Site
Bangkok, Thailand
Research Site
Banphaeo, Thailand
Research Site
Chiang Mai, Thailand
Research Site
Phutthamonthon, Thailand
Research Site
Ratchathewi, Thailand
Research Site
Hà Nội, Vietnam
Research Site
Haiphong, Vietnam
Research Site
Ho Chi Minh City, Vietnam
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.